OncoMatch/Clinical Trials/NCT06290505
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study
Is NCT06290505 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Durvalumab for esophageal cancer.
Treatment: Durvalumab — The purpose of this study is to investigate the effects of the addition of the stereotactic body radiotherapy and durvalumab to a well tolerated 2 week chemotherapy and radiation treatment regimen in people with esophageal cancer that is locally advanced or has spread to another area of the body (metastasized).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Esophageal Carcinoma
Biomarker criteria
Excluded: HER2 (ERBB2) positivity (IHC 2+ or more and HER2 gene amplification on in situ hybridisation)
Known tumour HER2 positivity (IHC 2+ or more and HER2 gene amplification on in situ hybridisation) if oligometastatic disease
Allowed: PD-L1 (CD274) expression
Tumour tissue ... should be available for PD-L1 and mismatch repair (MMR) protein expression ... Patients will not be selected by PD-L1 or MMR status.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Previous systemic therapy for oesophageal or GOJ carcinoma
Cannot have received: thoracic radiotherapy
Exception: Prior palliative radiotherapy to bony metastases is permitted
Previous thoracic radiotherapy. Prior palliative radiotherapy to bony metastases is permitted.
Cannot have received: anti-PD-1 therapy
Prior therapy with an anti-PD1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways
Lab requirements
Blood counts
WBC ≥ 2 x 10^9/L; ANC ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Haemoglobin ≥ 90g/L
Kidney function
Serum creatinine ≤ 1.5 x ULN; Creatinine clearance (CrCl) ≥ 40 mL/min using Cockroft-Gault formula
Liver function
Alanine transferase ≤ 2.5 x ULN; Aspartate transferase ≤ 2.5 x ULN; Total bilirubin ≤ 1.5 x ULN (≤ 5 x ULN if Gilbert's Syndrome)
Adequate bone marrow function ... Adequate liver function ... Adequate renal function ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06290505 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with ERBB2 alterations eligible?
No. ERBB2 positivity (IHC 2+ or more and HER2 gene amplification on in situ hybridisation) is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages